Ken Griffin Inmune Bio, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 12,400 shares of INMB stock, worth $67,704. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,400
Previous 21,400
42.06%
Holding current value
$67,704
Previous $251,000
56.57%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding INMB
# of Institutions
61Shares Held
4.66MCall Options Held
80KPut Options Held
41.8K-
Black Rock Inc. New York, NY813KShares$4.44 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA628KShares$3.43 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$3.26 Million45.87% of portfolio
-
Praetorian Pr LLC Rincon, PR485KShares$2.65 Million1.57% of portfolio
-
Geode Capital Management, LLC Boston, MA323KShares$1.76 Million0.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $98M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...